Table 5. Ongoing trials of neoadjuvant and adjuvant therapy with tyrosine kinase inhibitors.

Trial	Phase	Therapy	Population	Arms	Primary endpoint
EMERGING	II	Neoadjuvant	IIIA EGFR+	Erlotinib for 6 weeks, then 1 year postoperatively cisplatin/gemcitabine	ORR
NCT03203590	II	Neoadjuvant	II–IIIA EGFR+	Gefitinib for 8 weeks carboplatin/vinorelbine	2-year DFS
NeoADAURA	II	Neoadjuvant	II–IIIA EGFR+	Osimertinib ± platinum/pemetrexed platinum/pemetrexed	MPR
ALCHEMIST-ALK	III	Adjuvant	IB–IIIA ALK+	Crizotinib for 2 years placebo	OS
ALINA	III	Adjuvant	IB–IIIA ALK+	Alectinib for 2 years chemotherapy	DFS
NCT04302025	II	Neoadjuvant	IB–IIIB ALK+, ROS1+, NTRK+, BRAF+	Neoadjuvant ± adjuvant alectinib for 8 weeks entrectinib vemurafenib + cobimetinib	MPR
NCT03088930	II	Neoadjuvant	IA–IIIA ALK+ ROS1+, MET+	Crizotinib for 6 weeks	ORR
NCT01929200	II	Adjuvant	II–IIIA EGFR+	icotinib for 1-year adjuvant therapy vs. 2-year	RFS
NCT03349203	II	Neoadjuvant and Adjuvant	IIIB or oligometastasis EGFR+	Icotinib for 8 weeks before surgery and 2 years as adjuvant therapy	ORR
NCT03749213	II	Neoadjuvant	IIIA-N2 EGFR+	Icotinib for 8 weeks as neoadjuvant therapy and for 2 years as adjuvant therapy	ORR
NCT05165355	II	Adjuvant	IB–IIA EGFR+	Furmonertinib for 3 years as adjuvant therapy	2-year DFS
NCT04965831	II	Neoadjuvant and Adjuvant	IIIA–IIIB (N1-N2) EGFR+	Furmonertinib for 8 weeks before surgery and 2 years as adjuvant therapy	ORR
NCT04853342	III	Adjuvant	II–IIIA EGFR+	Furmonertinib versus placebo ± chemotherapy	DFS

ORR, overall response rate; DFS, disease-free survival; MPR, major pathological response; RFS, recurrence-free survival; OS, overall survival; EGFR+, EGFR-mutated; ALK+, ALK-rearranged; BRAF+, BRAF-mutated; NTRK+, NTRK-rearranged; ROS1+, ROS1-rearranged; MET+, MET-altered.